Aquestive Therapeutics Earnings Perspective: Return On Capital Employed According to data from Benzinga Pro, during Q1, Aquestive Therapeutics's (NASDAQ:AQST) reported sales totaled $12.27 million. Despite a 54.33% increase in earnings, the company posted a loss of $13.22 million. Benzinga · May 16, 2022
Earnings Outlook For Aquestive Therapeutics Aquestive Therapeutics (NASDAQ:AQST) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that Aquestive Therapeutics will report an earnings per share (EPS) of $-0.41. Benzinga · May 2, 2022
Looking Into Aquestive Therapeutics's Return On Capital Employed Benzinga Pro data, Aquestive Therapeutics (NASDAQ:AQST) reported Q4 sales of $11.08 million. Earnings fell to a loss of $28.95 million, resulting in a 98.87% decrease from last quarter. Benzinga · Mar 11, 2022
A Preview Of Aquestive Therapeutics's Earnings Aquestive Therapeutics (NASDAQ:AQST) is set to give its latest quarterly earnings report on Tuesday, 2022-03-08. Here's what investors need to know before the announcement. Analysts estimate that Aquestive Therapeutics will report an earnings per share (EPS) of $-0.47. Benzinga · Mar 7, 2022